Microbiome Therapeutics for Hepatic Encephalopathy

The use of Rifaximin in Patients with Cirrhosis

(2021) Paolo Caraceni et al.   HEPATOLOGY

Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals

(2021) Francesco Asnicar et al.   NATURE MEDICINE

Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy

(2021) Patricia P. Bloom et al.   Annals of Hepatology

Pathophysiology of Hepatic Encephalopathy

(2020) Ariel Jaffe et al.   Clinics in Liver Disease

Therapeutic microbes to tackle disease

(2020) Claire Ainsworth   NATURE

Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis

(2020) Elliot B. Tapper et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prolonged SARS‐Cov‐2 RNA Detection in Anal/Rectal Swabs and Stool Specimens in COVID‐19 Patients After Negative Conversion in Nasopharyngeal RT‐PCR Test

(2020) Vincent Kipkorir et al.   JOURNAL OF MEDICAL VIROLOGY

Probiotics: Promise, Evidence, and Hope

(2020) Alexander Khoruts et al.   GASTROENTEROLOGY

Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

(2020) Gianluca Ianiro et al.   GUT

Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis

(2020) Charlotte Woodhouse et al.   JOURNAL OF HEPATOLOGY

Microbiome metabolic therapies reduce microbiota-associated ammonia in ex vivo fecal samples from healthy subjects and patients with minimal hepatic encephalopathy and demonstrate improved tolerability over lactulose in a clinical study

(2020) Jasmohan S Bajaj et al.   JOURNAL OF HEPATOLOGY

Potential in vivo delivery routes of postbiotics

(2020) Amin Abbasi et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Chronic Liver Diseases and the Microbiome—Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease

(2020) Chathur Acharya et al.   GASTROENTEROLOGY

Long-term Outcomes after Fecal Microbiota Transplant in Cirrhosis

(2019) Jasmohan S. Bajaj et al.   GASTROENTEROLOGY

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis

(2019) Samuel P. Costello et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans

(2019) Caroline B. Kurtz et al.   Science Translational Medicine

PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial

(2019) Charlotte Alexandra Woodhouse et al.   BMJ Open

Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis

(2019) Stephen D. Skolnick et al.   TRENDS IN NEUROSCIENCES

Fecal Microbial Transplant Capsules are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial

(2019) Jasmohan S Bajaj et al.   HEPATOLOGY

Quinolone and Multidrug Resistance Predicts Failure of Antibiotic Prophylaxis of Spontaneous Bacterial Peritonitis

(2019) Marcus M Mücke et al.   CLINICAL INFECTIOUS DISEASES

Neuroinflammation in Murine Cirrhosis is Dependent on the Gut Microbiome and is Attenuated by Fecal Transplant

(2019) Runping Liu et al.   HEPATOLOGY

Probiotics and prebiotics in intestinal health and disease: from biology to the clinic

(2019) Mary Ellen Sanders et al.   Nature Reviews Gastroenterology & Hepatology

Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review & Network Meta-analysis

(2019) Radha K. Dhiman et al.   Clinical Gastroenterology and Hepatology

Lactulose Improves Cognition, Quality of Life and Gut Microbiota in Minimal Hepatic Encephalopathy: A Multi‐Center, Randomized Controlled Trial

(2019) Ji Yao Wang et al.   Journal of Digestive Diseases

Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease

(2019) Yi Duan et al.   NATURE

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant

(2019) Zachariah DeFilipp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interplay between the human gut microbiome and host metabolism

(2019) Alessia Visconti et al.   Nature Communications

A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

(2018) Sherief Abd-Elsalam et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Current understanding of the human microbiome

(2018) Jack A Gilbert et al.   NATURE MEDICINE

Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics

(2018) Janina A. Krumbeck et al.   Microbiome

Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy

(2018) Christian Schulz et al.   DIGESTIVE DISEASES

Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe

(2018) Javier Fernández et al.   JOURNAL OF HEPATOLOGY

Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

(2017) Jasmohan S. Bajaj et al.   HEPATOLOGY

Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis

(2017) Dai Ishikawa et al.   INFLAMMATORY BOWEL DISEASES

Targeting the gut-liver axis in liver disease

(2017) Reiner Wiest et al.   JOURNAL OF HEPATOLOGY

Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics

(2017) Glenn R. Gibson et al.   Nature Reviews Gastroenterology & Hepatology

Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases

(2017) Laura J Craven et al.   Open Forum Infectious Diseases

Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations

(2017) Nathaniel D. Chu et al.   PLoS One

Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis

(2016) A. Horvath et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Characterizing microbiota-independent effects of oligosaccharides on intestinal epithelial cells: insight into the role of structure and size

(2016) Peyman Akbari et al.   EUROPEAN JOURNAL OF NUTRITION

The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus

(2016) Annalisa Ricci et al.   JOURNAL OF CHEMOTHERAPY

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

(2016) María Úbeda et al.   JOURNAL OF HEPATOLOGY

Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy

(2016) Alba Moratalla et al.   LIVER INTERNATIONAL

Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances T reg and T H 17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding

(2016) Rui-Cong Chen et al.   TOXICOLOGY LETTERS

Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition

(2016) Dae J Kang et al.   Clinical and Translational Gastroenterology

Antibiotic-Induced Gut Microbiota Disruption Decreases TNF-α Release by Mononuclear Cells in Healthy Adults

(2016) Jacqueline M Lankelma et al.   Clinical and Translational Gastroenterology

Rifaximin, Microbiota Biology and Hepatic Encephalopathy

(2016) Cedric Peleman et al.   Clinical and Translational Gastroenterology

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome and Organic Acid Excretion in Irritable Bowel Syndrome

(2016) Andrés Acosta et al.   Clinical and Translational Gastroenterology

Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons

(2015) Jelena Vulevic et al.   BRITISH JOURNAL OF NUTRITION

Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis: Table 1

(2015) J M Ramos et al.   GUT

Methods to determine intestinal permeability and bacterial translocation during liver disease

(2015) Lirui Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis

(2015) Li-Na Zhao et al.   Clinics and Research in Hepatology and Gastroenterology

Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy

(2014) N. Kimer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

(2014) J. S. Bajaj et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial

(2014) Radha K. Dhiman et al.   GASTROENTEROLOGY

Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells

(2014) Shikha Bhatia et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway

(2014) J Park et al.   Mucosal Immunology

The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

(2014) Colin Hill et al.   Nature Reviews Gastroenterology & Hepatology

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial

(2014) Kapil Sharma et al.   Saudi Journal of Gastroenterology

Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing

(2013) Zhigang Zhang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

(2013) Dabo Xu et al.   GASTROENTEROLOGY

Effects of lactulose supplementation on performance, blood profiles, excreta microbial shedding ofLactobacillusandEscherichia coli, relative organ weight and excreta noxious gas contents in broilers

(2013) J. H. Cho et al.   JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION

Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial

(2013) Nitin Gupta et al.   LIVER INTERNATIONAL

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

BifidobacteriumCECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice

(2013) Paola Gauffin Cano et al.   Obesity

Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases?

(2013) L. K. Brahe et al.   Obesity Reviews

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

(2013) Jasmohan S. Bajaj et al.   PLoS One

Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota

(2012) Rebecca Wall et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model

(2012) Katerina Tsilingiri et al.   GUT

Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota

(2012) Matteo Garcovich   WORLD JOURNAL OF GASTROENTEROLOGY

Biologic properties and clinical uses of rifaximin

(2011) Herbert L DuPont   EXPERT OPINION ON PHARMACOTHERAPY

Bile Acid Is a Host Factor That Regulates the Composition of the Cecal Microbiota in Rats

(2011) K.B.M. Saiful Islam et al.   GASTROENTEROLOGY

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats

(2011) Cristina R. Bosoi et al.   HEPATOLOGY

Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)

(2010) Sandeep Singh Sidhu et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Bacterial, SCFA and gas profiles of a range of food ingredients following in vitro fermentation by human colonic microbiota

(2010) Emma Beards et al.   ANAEROBE

Pharmacotherapy for Hepatic Encephalopathy

(2010) Paula V. Phongsamran et al.   DRUGS

Enteric dysbiosis associated with a mouse model of alcoholic liver disease

(2010) Arthur W. Yan et al.   HEPATOLOGY

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

(2010) Zhi-Dong Jiang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system

(2010) Simone Maccaferri et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis

(2010) D.L. Shawcross et al.   JOURNAL OF HEPATOLOGY

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis

(2009) Rudolf Mennigen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles

(2009) E. L. Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of γδT and regulatory T cells of intestinal intraepithelial lymphocytes

(2009) Marianna Roselli et al.   INFLAMMATORY BOWEL DISEASES

Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy

(2008) Jasmohan S. Bajaj et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis

(2008) Vanessa Stadlbauer et al.   JOURNAL OF HEPATOLOGY

The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing

(2008) Les Dethlefsen et al.   PLOS BIOLOGY